This American Family Physician clinical review addresses a decision family physicians meet often. It reports that buprenorphine reduces overdose risk and all-cause mortality, each by more than 50%, and that discontinuation is common and often patient-driven.
Longer maintenance (over 12 months) and slow, individualised tapers of 2 mg a month or less were associated with lower overdose risk, less opioid use and higher taper completion. Adjunctive medicines can treat withdrawal symptoms, and harm reduction, including naloxone and continuing follow-up, is supported.
The optimal duration of maintenance is not known, so stopping should be supported, patient-centred and voluntary. For some patients, a sustained lower dose may be a more realistic goal than stopping.
The figures quoted are from US data. This is a narrative review rather than a trial, and the associations may partly reflect who chooses to taper slowly.
- Do not set a fixed end date for buprenorphine; the optimal duration is unknown.
- If a patient wants to stop, discuss a slow taper of 2 mg a month or less.
- Provide naloxone and arrange regular follow-up through and after the taper.
- Treat withdrawal symptoms with adjunctive medicines where needed.
- A sustained lower dose may be a reasonable endpoint.
Why it matters
The risks sit mostly in how treatment ends, and that is where a family physician can intervene.
Don't overread it
This is a narrative review of mostly observational evidence; the associations with slow tapering are not proof of benefit.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for family medicine, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free